Ocular Therapeutix (OCUL)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Ophthalmologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-14. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 22/100 (LOW), 43.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 15.93% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus — The Week’s Biotech Watchlist
- Ocular Therapeutix (OCUL) Stock Still Looks Pricey As 145% Gain Draws Scrutiny
- OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
- Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
- OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
- Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
- Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Cytopathology and Prognostic Accuracy of 15-GEP/PRAME: The Collaborative Ocular Oncology Group Study 2. — JAMA Ophthalmol 2026 Oct 15 PMID 42879143
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Ocular Therapeutix.
Full OCUL Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.